SCHEMBL26075158

SCHEMBL26075158

CCOc1cccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MAPT P10636 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ PDE10A Q9Y233 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ ACACA Q13085 1/20 0.41
▸ GRM5 P41594 2/20 0.40
▸ FYN P06241 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ KIT P10721 2/20 0.39
▸ DHODH Q02127 2/20 0.39
▸ NR3C1 P04150 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075150 0.90 MEN1 (0.46) MEN1KMT2ASMN1; SMN2MAPTHPGD
SCHEMBL26075154 0.90 KDM4E (0.50) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL26075134 0.89 PTGS2 (0.47) MEN1KMT2ASMN1; SMN2MAPTHPGD
SCHEMBL26075172 0.87 MEN1 (0.44) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL23590315 0.87 KDM4E (0.66) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL29997289 0.87 KDM4E (0.66) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL26075197 0.85 DHODH (0.44) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL26075179 0.84 KDM4E (0.47) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL26075144 0.82 MAP4K4 (0.43) MEN1KMT2AKDM4ESMN1; SMN2HSD17B10
SCHEMBL26075191 0.82 DHODH (0.51) MEN1KMT2AKDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD MEN1 2373/4885KMT2A 1314/4885KDM4E 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback